Skip to main content
Premium Trial:

Request an Annual Quote

Lucence Diagnostics Names Myanmar Distribution Partner for Cancer Dx Tests

NEW YORK (GenomeWeb) – Lucence Diagnostics said today that it has partnered with Myanmar-based firm Mascots Medical and Laboratory Centre to distribute Lucence's blood-based cancer diagnostic tests and treatment in Myanmar.

Under the terms of the agreement, Mascots will distribute Lucence's blood tests, which detect DNA fragments shed by a tumor into the blood to identify cancer-driving mutations. The assays target a variety of cancers, including breast, colon, lung, and pancreatic cancers.

Financial and other terms of the agreement were not disclosed.

"Through this partnership with Lucence, we can provide simple blood tests to help our people detect cancer as early as possible, understand their risk of cancer, and provide them with a better choice of cancer treatment," Mascots Director Thynn Myo Myo Aye said in a statement.

The distribution deal in Myanmar follows similar distribution agreements covering Lucence's cancer detection assays in Asia during the last few months, including agreements in Thailand, Singapore, and the Philippines.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.